FDA rejects ivonescimab for lung cancer - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA rejects ivonescimab for lung cancer

  • By

  • Mouj Hijazi

  • November 16, 2026

  • 2 min

Share

Objective:

The article reports the FDA’s decision on ivonescimab plus chemotherapy for previously treated EGFR-mutated NSCLC, the agency’s rationale, and the HARMONi trial results supporting the application.

Approach:
  • Regulatory decision: The FDA issued a Complete Response Letter, saying the application could not be approved in its present form because substantial evidence of effectiveness had not been established without a statistically significant overall-survival improvement.
  • Evidence reviewed: The application was supported by HARMONi, a global, randomized, double-blind phase 3 trial in patients with EGFR-mutated, locally advanced or metastatic nonsquamous NSCLC previously treated with a third-generation EGFR TKI. It compared ivonescimab plus platinum-containing chemotherapy with placebo plus chemotherapy.
Key Findings:
  • HARMONi met its dual primary progression-free survival endpoints.
  • Overall survival showed a favorable trend but did not reach statistical significance.
  • The FDA said the progression-free survival benefit alone did not support a favorable benefit-risk profile or establish substantial evidence of effectiveness.
Interpretation:

Summit Therapeutics said ivonescimab remains investigational and is not approved in the United States; it has marketing authorization in China.

Limitations:
  • The context does not provide trial participant numbers, effect estimates, or detailed safety results.
Conclusion:

Summit said development continues in other settings, including first-line NSCLC and colorectal cancer.

Sources:

Original Source(s)

Related Content